Compare · ELV vs LH
ELV vs LH
Side-by-side comparison of Elevance Health Inc. (ELV) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.50B, about 3.2x LH ($27.39B).
- LH has hit the wire 12 times in the past 4 weeks while ELV has been quiet.
- LH has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Labcorp Holdings Inc.
- Price
- $398.89-0.87%
- $337.70-0.56%
- Market cap
- $86.50B
- $27.39B
- 1M return
- -
- +12.09%
- 1Y return
- -
- +21.29%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 0
- 12
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Latest LH
- Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
- Director Anderson Kerrii B sold $954,060 worth of shares (3,000 units at $318.02) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 6,563 units (SEC Form 4)
- Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Host Investor Day on September 10, 2026
- Labcorp Holdings Inc. filed SEC Form 8-K: Leadership Update
- President & CEO Schechter Adam H sold $1,495,808 worth of shares (4,669 units at $320.37) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 102,565 units (SEC Form 4)
- Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
- EVP, Chief Marketing Officer Summy Amy B. sold $283,428 worth of shares (924 units at $306.74), decreasing direct ownership by 12% to 6,956 units (SEC Form 4)
- SEC Form 10-Q filed by Labcorp Holdings Inc.